Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer.
about
An integrated psychological strategy for advanced colorectal cancer patientsIrinotecan chemotherapy combined with fluoropyrimidines versus irinotecan alone for overall survival and progression-free survival in patients with advanced and/or metastatic colorectal cancerIrinotecan chemotherapy combined with fluoropyrimidines versus irinotecan alone for advanced and/or metastatic colorectal cancerIrinotecan chemotherapy combined with fluoropyrimidines versus irinotecan alone for advanced and/or metastatic colorectal cancerSecond-line chemotherapy in advanced and metastatic CRCUGT1A1 gene variations and irinotecan treatment in patients with metastatic colorectal cancerPhase II study of neoadjuvant 5-FU + leucovorin + CPT-11 in patients with resectable liver metastases from colorectal adenocarcinomaPhase I/II study of first-line irinotecan combined with 5-fluorouracil and folinic acid Mayo Clinic schedule in patients with advanced colorectal cancerIrinotecan plus folinic acid/continuous 5-fluorouracil as simplified bimonthly FOLFIRI regimen for first-line therapy of metastatic colorectal cancerRaltitrexed (Tomudex) administration in patients with relapsed metastatic colorectal cancer after weekly irinotecan/5-Fluorouracil/Leucovorin chemotherapyA prospective evaluation of treatment with Selective Internal Radiation Therapy (SIR-spheres) in patients with unresectable liver metastases from colorectal cancer previously treated with 5-FU based chemotherapyPharmacologic resistance in colorectal cancer: a reviewIrinotecan, a key chemotherapeutic drug for metastatic colorectal cancerMolecular Insights into Microbial -Glucuronidase Inhibition to Abrogate CPT-11 ToxicityEffect of non-steroidal anti-inflammatory drugs on colon carcinoma Caco-2 cell responsiveness to topoisomerase inhibitor drugsThe changing face of chemotherapy in colorectal cancerFactors predicting efficacy of oxaliplatin in combination with 5-fluorouracil (5-FU) +/- folinic acid in a compassionate-use cohort of 481 5-FU-resistant advanced colorectal cancer patientsTernary combination of irinotecan, fluorouracil-folinic acid and oxaliplatin: results on human colon cancer cell lines5-fluorouracil modulated by leucovorin, methotrexate and mitomycin: highly effective, low-cost chemotherapy for advanced colorectal cancerOxaliplatin and protracted venous infusion of 5-fluorouracil in patients with advanced or relapsed 5-fluorouracil pretreated colorectal cancerSecond-line systemic therapy for metastatic colorectal cancer.Oral capecitabine vs intravenous 5-fluorouracil and leucovorin: integrated efficacy data and novel analyses from two large, randomised, phase III trialsA two-stage hepatectomy procedure combined with portal vein embolization to achieve curative resection for initially unresectable multiple and bilobar colorectal liver metastases.Combined liver resection and reconstruction of the supra-renal vena cava: the Paul Brousse experience.Randomized phase II study of irinotecan plus mitomycin C vs. oxaliplatin plus mitomycin C in patients with advanced fluoropyrimidine/leucovorin-pretreated colorectal cancer.Irinotecan is active in chemonaive patients with metastatic gastric cancer: a phase II multicentric trial.Phase II trial of oxaliplatin and tegafur/uracil and oral folinic acid for advanced or metastatic colorectal cancer in elderly patients.A phase I dose-finding clinical pharmacokinetic study of an oral formulation of irinotecan (CPT-11) administered for 5 days every 3 weeks in patients with advanced solid tumours.Multicenter phase II study of gemcitabine and oxaliplatin (GEMOX) as second-line chemotherapy in colorectal cancer patients pretreated with 5-fluorouracil plus irinotecan.Phase I dose escalation study of gemcitabine plus irinotecan in advanced solid tumors.The efficacy of a modified chronomodulated infusion of oxaliplatin, 5-fluorouracil and leucovorin in advanced colorectal cancer (preliminary data).A multicenter phase II study of belotecan, a new camptothecin analogue, in elderly patients with previously untreated, extensive-stage small cell lung cancer.Generalizability of toxicity data from oncology clinical trials to clinical practice: toxicity of irinotecan-based regimens in patients with metastatic colorectal cancerRegulation of UGT1A1 and HNF1 transcription factor gene expression by DNA methylation in colon cancer cellsAdjuvant therapy after resection of colorectal liver metastases: the predictive value of the MSKCC clinical risk score in the era of modern chemotherapyOptimizing collection of adverse event data in cancer clinical trials supporting supplemental indications.Effects of mannose-binding lectin polymorphisms on irinotecan-induced febrile neutropenia.Irinotecan-Induced Gastrointestinal Dysfunction Is Associated with Enteric Neuropathy, but Increased Numbers of Cholinergic Myenteric Neurons.Cost effectiveness of pharmacogenetic testing for uridine diphosphate glucuronosyltransferase 1A1 before irinotecan administration for metastatic colorectal cancer.Management of stage IV rectal cancer: palliative options.
P2860
Q21245616-84EEDB97-62B0-4C88-8125-F93962A39CE3Q24186145-E3CE2BE2-20EA-4E38-B652-0BEC5DDEE66AQ24200737-AD486B9D-D6FB-46FC-AD9A-483508FAF54DQ24234555-D5030294-41EF-49E1-B831-0805996DC298Q24241235-F617DEA8-FCF4-48C1-809F-BE9B9263DDE9Q24648015-F34A67CD-547D-4683-ABC9-FB9FBB2BF918Q24792609-68CB9F6F-B5FD-4012-A51B-560D056781FFQ24795149-1AAF73C1-E386-4766-BEFB-79A029E33E38Q24795784-16FB48CB-6793-4775-BFF9-7C05C6F8EFD3Q24801466-8449A878-15B8-4C03-B067-FBB0B79F0287Q24811929-47128B75-AAA2-42DC-9DC5-E43B1C619BC0Q26769850-7C4E589B-59AE-40DD-B1FD-18A0069B422AQ26775949-FD736A75-F80B-4091-A506-A3F0991F2E1DQ27678202-465883B3-7A3F-4C72-8FF0-387A76060344Q28192910-645A1B1A-832D-4E80-B47E-600CBA1A983FQ28345461-8A426E05-C7A8-4FFC-A15A-108A16163999Q28346039-533E1353-9E36-4FD2-AD19-9A5AC60A6ED0Q28350941-CD6EC653-152D-47F6-9C70-17D9FF42B00DQ28362939-B0C70D0A-B951-4417-8308-159BD2564352Q28364999-E54B67DB-074F-43AE-8D29-D0BDDEE433EAQ30238760-5C9C1DCD-C019-4101-8235-3747FF5449CDQ30913489-4A6AF342-250C-4299-B4E3-E24E5D66E0A3Q33209415-95194EC9-00F6-4A14-AD44-C676568A594BQ33247711-756CEB41-F418-4A16-BA7B-3760269C1785Q33341120-33704CB2-5F24-45AF-82CC-B01888FAFAE0Q33349888-872926A3-F351-45BC-9140-4207E130D8D0Q33368070-6785CEF9-B859-4206-AF12-E1F04403B4A1Q33370792-DBF6B8B3-CDBE-428F-912E-DA96E28F6457Q33371015-BDFEE82A-0857-4932-B261-4FC9938FC323Q33387673-CFF5BB2C-DAB9-465F-89C3-EC77F8F92A23Q33389163-4155EE94-1573-43F9-9BBF-F23BEF656776Q33409548-DA033880-3AD9-4A4E-B71A-D183A3AE99D0Q33519035-5C4DD0DE-6089-41AF-8D19-15B1531ABDFDQ33526045-046BE1D7-9EE3-4D84-A97E-57A8BC03F501Q33558347-F3C4AAB1-3260-4692-94F1-73C87741A212Q33710475-A6C0291B-40B4-4C3F-93F4-7F09CB46F9CBQ33712655-F28BFEF8-FDE3-4C5A-A1F6-FE8C5E44E715Q33774788-4935E844-DA76-4FE8-8778-6510E90A881BQ33783293-11BE8E61-3C94-4CED-8DCB-48693EB94ECBQ33849034-9DA8F344-3B49-4D6C-A48F-8C98DF405F67
P2860
Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer.
description
1998 nî lūn-bûn
@nan
1998 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
1998 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
1998年の論文
@ja
1998年論文
@yue
1998年論文
@zh-hant
1998年論文
@zh-hk
1998年論文
@zh-mo
1998年論文
@zh-tw
1998年论文
@wuu
name
Randomised trial of irinotecan ...... metastatic colorectal cancer.
@ast
Randomised trial of irinotecan ...... metastatic colorectal cancer.
@en
Randomised trial of irinotecan ...... metastatic colorectal cancer.
@nl
type
label
Randomised trial of irinotecan ...... metastatic colorectal cancer.
@ast
Randomised trial of irinotecan ...... metastatic colorectal cancer.
@en
Randomised trial of irinotecan ...... metastatic colorectal cancer.
@nl
prefLabel
Randomised trial of irinotecan ...... metastatic colorectal cancer.
@ast
Randomised trial of irinotecan ...... metastatic colorectal cancer.
@en
Randomised trial of irinotecan ...... metastatic colorectal cancer.
@nl
P2093
P1433
P1476
Randomised trial of irinotecan ...... h metastatic colorectal cancer
@en
P2093
E Van Cutsem
H Bleiberg
K Possinger
N Niederle
P304
P356
10.1016/S0140-6736(98)03085-2
P407
P577
1998-10-01T00:00:00Z